Zingerone suppresses angiogenesis  via  inhibition of matrix metalloproteinases during tumor development

Woom-Yee Bae; Jae-Sun Choi; Ja-Eun Kim; Chan Park; Joo-Won Jeong

doi:10.18632/oncotarget.10030

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Zingerone suppresses angiogenesis via inhibition of matrix metalloproteinases during tumor development

Woom-Yee Bae, Jae-Sun Choi, Ja-Eun Kim, Chan Park and Joo-Won Jeong _

PDF | HTML | How to cite

Oncotarget. 2016; 7:47232-47241. https://doi.org/10.18632/oncotarget.10030

Metrics: PDF 2183 views | HTML 2703 views | ?

Abstract

Woom-Yee Bae1,*, Jae-Sun Choi1,*, Ja-Eun Kim2,3, Chan Park1,2, Joo-Won Jeong1,2

1Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea

2Department of Anatomy and Neurobiology, School of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea

3Department of Pharmacology, School of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea

*These authors contributed equally to this work

Correspondence to:

Joo-Won Jeong, email: [email protected]

Keywords: zingerone, angiogenesis, cancer, matrix metalloproteinases, JNK

Received: April 25, 2016 Accepted: June 04, 2016 Published: June 14, 2016

ABSTRACT

Angiogenesis is an essential step for tumor survival and progression, and the inhibition of angiogenesis is a good strategy for tumor therapeutics. In this study, we investigated the therapeutic effect of zingerone in a mouse tumor model. Zingerone suppressed tumor progression and tumor angiogenesis. Moreover, we found that zingerone inhibited the angiogenic activities of endothelial cells by both direct and indirect means. A mechanistic study showed that the activities of MMP-2 and MMP-9 in tumor cells were decreased by treatment with zingerone. Interestingly, zingerone-mediated inhibition of MMP-2 and MMP-9 was involved in the JNK pathway. In conclusion, zingerone showed strong anti-angiogenic activity via the inhibition of MMP-2 and MMP-9 during tumor progression, suggesting that zingerone may be a potential therapeutic drug for human cancers.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10030

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Zingerone suppresses angiogenesis via inhibition of matrix metalloproteinases during tumor development

Abstract